We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Regulator of Gene Transcription Identified as Potential Anticancer Drug Target

By LabMedica International staff writers
Posted on 14 Feb 2016
The enzyme MLL1 (histone-lysine N-methyltransferase 2A) was identified as a potential target for anticancer drugs after researchers found that its inhibition prevented tumor development by shutting down the DNA damage response mechanism and suppressed inflammation by blocking the activity of proliferation-promoting genes.

MLL is a histone methyltransferase deemed a positive global regulator of gene transcription. More...
This protein belongs to the group of histone-modifying enzymes and is involved in the epigenetic maintenance of transcriptional memory. Previous observations linked this transcription-associated methyltransferase and oncoprotein to the DNA damage response (DDR), which led investigators at the University of Pennsylvania (Philadelphia, USA) to examine the role of MLL1 in cancer development and in the appearance of age-related inflammation.

They reported in the February 1, 2016, issue of the journal Genes & Development that MLL1 displayed direct epigenetic control over pro-proliferative cell cycle genes. Inhibition of MLL1 repressed expression of pro-proliferative cell cycle regulators required for DNA replication and DDR activation, thus disabling age-related inflammation expression. However, these effects of MLL1 inhibition on age-related inflammation gene expression did not impair oncogene-induced senescence (OIS) and, abolished the ability of the age-related inflammation to enhance cancer cell proliferation. These results demonstrated that MLL1 inhibition may be a powerful and effective strategy for blocking cancerous growth through the direct epigenetic regulation of proliferation-promoting genes.

"Since tumor-promoting inflammation is one of the hallmarks of cancer, these findings suggest that MLL1 inhibitors may be highly potent anticancer drugs through both direct epigenetic effects on proliferation-promoting genes, as well as through the inhibition of inflammation in the tumor microenvironment," said first author Dr. Brian Capell, a medical fellow in epigenetics and dermatology at the University of Pennsylvania. "In cancer, this could be a potent one-two punch, by blocking both proliferation-promoting genes as well as the cancerous inflammation. One could imagine taking an MLL1 inhibitor as a primary treatment, but also as an adjuvant therapy to tamp down the rampant inflammation caused by drugs like chemotherapies."

Related Links:

University of Pennsylvania



Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
Rapid Molecular Testing Device
FlashDetect Flash10
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.